Lipophilic statins and risk for hepatocellular carcinoma and death in patients with chronic viral hepatitis: Results from a nationwide Swedish population
Annals of Internal Medicine Aug 26, 2019
Simon TG, Duberg AS, Aleman S, et al. - Via analyzing data from a prospective propensity score-matched cohort of 16,668 adults, researchers determined the association between lipophilic or hydrophilic statin use and hepatocellular carcinoma (HCC) incidence and mortality in a nationwide population with viral hepatitis. Ten-year HCC risk was significantly lower among lipophilic statin users—but not hydrophilic statin users—compared with matched nonusers. The inverse relationship between lipophilic statins and HCC risk appeared to be dose-dependent. Compared with nonusers, 10-year HCC risk was lowest with ≥ 600 lipophilic statin cumulative defined daily doses, and 10-year mortality was significantly lower among both lipophilic and hydrophilic statin users. Overall, lipophilic statins were related to significantly reduced HCC incidence and mortality. A relationship between hydrophilic statins and decreased risk for HCC was not observed.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries